Thymosin Beta-4 Stabilization via Phosphate Buffering

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Thymosin beta 4 (Tβ4) experiences chemical and physical instability during storage, leading to decreased biological activity and the formation of decomposition products such as sulfoxide, which hinders its therapeutic effectiveness in pharmaceutical formulations.

Innovation Solution

A stabilized external preparation comprising Tβ4 with phosphate as a buffer, propylene glycol as an additive, and sodium carboxymethyl cellulose as a viscosifier, maintained at a pH of 5.7 ± 0.1, to minimize denaturation and oxidation, thereby maintaining biological activity and stability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If Tβ4 is stored for prolonged periods, then therapeutic effects are maintained, but chemical decomposition occurs forming Tβ4 sulfoxide which reduces biological activity

Engineering Contradiction:

Improvestorage stabilityVSAvoidbiological activity

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent introduces phosphate buffer as an intermediary substance that mediates between Tβ4 and the oxidative environment. The phosphate buffer system maintains pH stability and creates a protective chemical environment that prevents oxidation of methionine residues, thereby preserving Tβ4's biological activity during prolonged storage

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent optimizes specific parameters including pH (maintained at physiological range by phosphate buffer), ionic strength, and temperature conditions. By controlling these parameters, the chemical decomposition rate of Tβ4 is reduced, allowing prolonged storage while maintaining biological activity above 80%

Inventive Principle:

Principle #35Parameter changes

2Stability of the object's composition

If Tβ4 is stored under refrigerated conditions, then physical instability such as aggregation and precipitation occurs, but chemical decomposition still happens

Engineering Contradiction:

Improvephysical stabilityVSAvoidbiological activity

Core Design Contradiction:

Stability of the object's compositionVSReliability

Solution Approach 1:

The patent creates a composite formulation system where Tβ4 is combined with phosphate buffer, sodium chloride, and other excipients in specific ratios. This composite system provides both physical stability (preventing aggregation and precipitation) and chemical stability (preventing oxidation), maintaining biological activity during refrigerated storage

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The phosphate buffer system creates a chemically inert environment that protects Tβ4 from oxidation. The buffer maintains a stable ionic environment that prevents unwanted chemical reactions, effectively creating a protective atmosphere around the peptide molecule during storage

Inventive Principle:

Principle #39Inert atmosphere (Inert environment)

3Duration of action of stationary object

If methionine in Tβ4 is oxidized to form sulfoxide, then storage time increases, but pharmacological activity changes due to different behavior in actin polymerization and anti-inflammatory action

Engineering Contradiction:

Improvestorage periodVSAvoidpharmacological activity change

Core Design Contradiction:

Duration of action of stationary objectVSObject-generated harmful factors

Solution Approach 1:

The phosphate buffer system provides preliminary protection against oxidation by maintaining optimal pH conditions and creating a reducing environment. This preliminary anti-action prevents the formation of Tβ4 sulfoxide before it can occur, preserving the original pharmacological activity of Tβ4 throughout the storage period

Inventive Principle:

Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The preparation effectively maintains Tβ4's stability and biological activity over prolonged periods, reducing the formation of sulfoxide and multimers, ensuring consistent therapeutic effects.

Implementation Method 1

comprising: 0.0314 wt% thymosin beta 4 (Tβ4); 0.147 wt% sodium phosphate dibasic as a buffer; HCl solution to adjust the pH of the preparation to 5.7 ± 0.1

Methodology Applied

Scientific EffectBuffering:

Implementation Method 2

1.05 wt% propylene glycol as an additive... minimizing the generation of Tβ4 sulfoxide through oxidation

Methodology Applied

Scientific EffectOxidation prevention: Oxidation

Implementation Method 3

2.63 wt% sodium carboxymethyl cellulose as a viscosifier... Physical instability refers to denaturation, aggregation and precipitation

Methodology Applied

Scientific EffectViscosification:

Data Source

PatentEP3590497B1Stabilized external use agent comprising thymosin beta-4 as effective ingredient

Publication Date: 2023.03.29 HLB THERAPEUTICS CO LTD

Figure 1

AI summary

The present invention relates to a stabilized external use agent comprising thymosin beta-4 as an effective ingredient and, more particularly, to an external use agent having therapeutically effective Tβ4 improved in biological activity and stability. Through the improvement, the external use according to the present invention can maintain the biological activity of Tβ4 and minimize the generation of Tβ4 sulfoxide attributed to an oxidation reaction and the generation of multimers attributed to aggregation, thereby providing Tβ4 in a stable state.